semaglutide and mcas A newly published case series reports that GLP-1 receptor agonists (like tirzepatide) may significantly improve symptoms in patients with mast cell activation syndrome (MCAS), even in those without diabetes or CagriSema vs Semaglutide: Dual Amylin/GLP-1

This trial observed statistically significant improvements in quality of life scores, weight loss, 6-min walk distance, C-reactive protein levels, and N-terminal proB-type natriuretic peptide levels

However, findings related to GDM, PIH, and preeclampsia are inconsistent, likely due to heterogeneity in study designs, diagnostic criteria, and the inclusion of varying populations and treatments

It is valid for encounters where the provider documents diabetic neuropathy without further classifying it as mononeuropathy, polyneuropathy, autonomic neuropathy, or amyotrophy

In addition, researchers can use sonication if available or very gently roll/swirl the vial

Science review: carnitine in the treatment of valproic acid-induced toxicity - what is the evidence

The effect of INSL-5 on glucose homeostasis is less clear